Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2016

Open Access 01-12-2016 | Research article

Symptom profiles and inflammatory markers in moderate to severe COPD

Authors: Huong Q. Nguyen, Jerald R. Herting, Kenneth C. Pike, Sina A. Gharib, Gustavo Matute-Bello, Soo Borson, Ruth Kohen, Sandra G. Adams, Vincent S. Fan

Published in: BMC Pulmonary Medicine | Issue 1/2016

Login to get access

Abstract

Background

Physical and psychological symptoms are the hallmark of patients’ subjective perception of their illness. The purpose of this analysis was to determine if patients with COPD have distinctive symptom profiles and to examine the association of symptom profiles with systemic biomarkers of inflammation.

Methods

We conducted latent class analyses of three physical (dyspnea, fatigue, and pain) and two psychological symptoms (depression and anxiety) in 302 patients with moderate to severe COPD using baseline data from a longitudinal observational study of depression in COPD. Systemic inflammatory markers included IL1, IL8, IL10, IL12, IL13, INF, GM-CSF, TNF-α (levels >75thcentile was considered high); and CRP (levels >3 mg/L was considered high). Multinominal logistic regression models were used to examine the association between symptom classes and inflammation while adjusting for key socio-demographic and disease characteristics.

Results

We found that a 4-class model best fit the data: 1) low physical and psychological symptoms (26%, Low-Phys/Low-Psych), 2) low physical but moderate psychological symptoms (18%, Low-Phys/Mod Psych), 3) high physical but moderate psychological symptoms (25%, High-Phys/Mod Psych), and 4) high physical and psychological symptoms (30%, High-Phys/High Psych). Unadjusted analyses showed associations between symptom class with high levels of IL7, IL-8 (p ≤ .10) and CRP (p < .01). In the adjusted model, those with a high CRP level were less likely to be in the High-Phys/Mod-Psych class compared to the Low-Phys/Low-Psych (OR: 0.41, 95%CI 0.19, 0.90) and Low-Phys/Mod-Psych classes (OR: 0.35, 95%CI 0.16, 0.78); elevated CRP was associated with in increased odds of being in the High-Phys/High-Psych compared to the High-Phys/Mod-Psych class (OR: 2.22, 95%CI 1.08, 4.58). Younger age, having at least a college education, oxygen use and depression history were more prominent predictors of membership in the higher symptom classes.

Conclusions

Patients with COPD can be classified into four distinct symptom classes based on five commonly co-occurring physical and psychological symptoms. Systemic biomarkers of inflammation were not associated with symptom class. Additional work to test the reliability of these symptom classes, their biological drivers and their validity for prognostication and tailoring therapy in larger and more diverse samples is needed.

Trial registration

Clinicaltrials.gov, NCT01074515.
Literature
1.
go back to reference Garcia-Aymerich J, Gomez FP, Benet M, et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax. 2011;66(5):430–7.CrossRefPubMed Garcia-Aymerich J, Gomez FP, Benet M, et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax. 2011;66(5):430–7.CrossRefPubMed
2.
go back to reference Rennard SI, Locantore N, Delafont B, et al. Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. Ann Am Thorac Soc. 2015;12(3):303–12.CrossRefPubMed Rennard SI, Locantore N, Delafont B, et al. Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. Ann Am Thorac Soc. 2015;12(3):303–12.CrossRefPubMed
3.
go back to reference Park SK, Larson JL. Symptom cluster, healthcare use and mortality in patients with severe chronic obstructive pulmonary disease. J Clin Nurs. 2014;23(17–18):2658–71.CrossRefPubMedPubMedCentral Park SK, Larson JL. Symptom cluster, healthcare use and mortality in patients with severe chronic obstructive pulmonary disease. J Clin Nurs. 2014;23(17–18):2658–71.CrossRefPubMedPubMedCentral
4.
go back to reference Park SK, Meldrum CA, Larson JL. Subgroup analysis of symptoms and their effect on functioning, exercise capacity, and physical activity in patients with severe chronic obstructive pulmonary disease. Heart Lung. 2013;42(6):465–72.CrossRefPubMedPubMedCentral Park SK, Meldrum CA, Larson JL. Subgroup analysis of symptoms and their effect on functioning, exercise capacity, and physical activity in patients with severe chronic obstructive pulmonary disease. Heart Lung. 2013;42(6):465–72.CrossRefPubMedPubMedCentral
5.
go back to reference Clark N, Fan VS, Slatore CG, et al. Dyspnea and pain frequently co-occur among Medicare managed care recipients. Ann Am Thorac Soc. 2014;11(6):890–7.CrossRefPubMedPubMedCentral Clark N, Fan VS, Slatore CG, et al. Dyspnea and pain frequently co-occur among Medicare managed care recipients. Ann Am Thorac Soc. 2014;11(6):890–7.CrossRefPubMedPubMedCentral
6.
go back to reference Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46–56.CrossRefPubMedPubMedCentral Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46–56.CrossRefPubMedPubMedCentral
7.
go back to reference Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344(13):961–6.CrossRefPubMed Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344(13):961–6.CrossRefPubMed
8.
go back to reference Eagan TM, Ueland T, Wagner PD, et al. Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study. Eur Respir J. 2010;35(3):540–8.CrossRefPubMed Eagan TM, Ueland T, Wagner PD, et al. Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study. Eur Respir J. 2010;35(3):540–8.CrossRefPubMed
9.
go back to reference Al-shair K, Kolsum U, Dockry R, Morris J, Singh D, Vestbo J. Biomarkers of systemic inflammation and depression and fatigue in moderate clinically stable COPD. Respir Res. 2011;12:3.CrossRefPubMedPubMedCentral Al-shair K, Kolsum U, Dockry R, Morris J, Singh D, Vestbo J. Biomarkers of systemic inflammation and depression and fatigue in moderate clinically stable COPD. Respir Res. 2011;12:3.CrossRefPubMedPubMedCentral
10.
go back to reference Marinho PE, Castro CM, Raposo MC, Guerra RO, de Andrade AD. Depressive symptoms, inflammatory markers and body composition in elderly with and without chronic obstructive pulmonary disease (COPD). Arch Gerontol Geriatr. 2012;54(3):453–8.CrossRefPubMed Marinho PE, Castro CM, Raposo MC, Guerra RO, de Andrade AD. Depressive symptoms, inflammatory markers and body composition in elderly with and without chronic obstructive pulmonary disease (COPD). Arch Gerontol Geriatr. 2012;54(3):453–8.CrossRefPubMed
11.
go back to reference Hanania NA, Mullerova H, Locantore NW, et al. Determinants of Depression in the ECLIPSE Chronic Obstructive Pulmonary Disease Cohort. Am J Respir Crit Care Med. 2011;183(5):604–11.CrossRefPubMed Hanania NA, Mullerova H, Locantore NW, et al. Determinants of Depression in the ECLIPSE Chronic Obstructive Pulmonary Disease Cohort. Am J Respir Crit Care Med. 2011;183(5):604–11.CrossRefPubMed
12.
go back to reference Janssen DJ, Mullerova H, Agusti A, et al. Persistent systemic inflammation and symptoms of depression among patients with COPD in the ECLIPSE cohort. Respir Med. 2014;108(11):1647–54.CrossRefPubMed Janssen DJ, Mullerova H, Agusti A, et al. Persistent systemic inflammation and symptoms of depression among patients with COPD in the ECLIPSE cohort. Respir Med. 2014;108(11):1647–54.CrossRefPubMed
13.
go back to reference Quint JK, Baghai-Ravary R, Donaldson GC, Wedzicha JA. Relationship between depression and exacerbations in chronic obstructive pulmonary disease. Eur Respir J. 2008;32(1):53–60. Quint JK, Baghai-Ravary R, Donaldson GC, Wedzicha JA. Relationship between depression and exacerbations in chronic obstructive pulmonary disease. Eur Respir J. 2008;32(1):53–60.
14.
go back to reference Spitzer RL, Williams JB, Gibbon M, First MB. The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. Arch Gen Psychiatry. 1992;49(8):624–9.CrossRefPubMed Spitzer RL, Williams JB, Gibbon M, First MB. The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. Arch Gen Psychiatry. 1992;49(8):624–9.CrossRefPubMed
15.
go back to reference Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM. Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest. 1998;113(3):619–24.CrossRefPubMed Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM. Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest. 1998;113(3):619–24.CrossRefPubMed
16.
go back to reference Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987;42(10):773–8.CrossRefPubMedPubMedCentral Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987;42(10):773–8.CrossRefPubMedPubMedCentral
17.
go back to reference Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.CrossRefPubMed Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.CrossRefPubMed
18.
go back to reference Ng TP, Niti M, Tan WC, Cao Z, Ong KC, Eng P. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med. 2007;167(1):60–7.CrossRefPubMed Ng TP, Niti M, Tan WC, Cao Z, Ong KC, Eng P. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med. 2007;167(1):60–7.CrossRefPubMed
19.
go back to reference Choudhury G, Rabinovich R, MacNee W. Comorbidities and systemic effects of chronic obstructive pulmonary disease. Clin Chest Med. 2014;35(1):101–30.CrossRefPubMed Choudhury G, Rabinovich R, MacNee W. Comorbidities and systemic effects of chronic obstructive pulmonary disease. Clin Chest Med. 2014;35(1):101–30.CrossRefPubMed
20.
go back to reference Muthen B. Latent variable analysis: Growth mixture modeling and related techniques for longitudinal data. In: Kaplan D, editor. Handbook of quantitative methodology for the social sciences. Newbury Park: Sage; 2004. p. 345–68. Muthen B. Latent variable analysis: Growth mixture modeling and related techniques for longitudinal data. In: Kaplan D, editor. Handbook of quantitative methodology for the social sciences. Newbury Park: Sage; 2004. p. 345–68.
21.
go back to reference Parshall MB, Schwartzstein RM, Adams L, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185(4):435–52.CrossRefPubMed Parshall MB, Schwartzstein RM, Adams L, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185(4):435–52.CrossRefPubMed
22.
go back to reference Singh D, Fox SM, Tal-Singer R, Bates S, Riley JH, Celli B. Altered gene expression in blood and sputum in COPD frequent exacerbators in the ECLIPSE cohort. PLoS One. 2014;9(9):e107381.CrossRefPubMedPubMedCentral Singh D, Fox SM, Tal-Singer R, Bates S, Riley JH, Celli B. Altered gene expression in blood and sputum in COPD frequent exacerbators in the ECLIPSE cohort. PLoS One. 2014;9(9):e107381.CrossRefPubMedPubMedCentral
23.
go back to reference Fan VS, Gharib SA, Martin TR, Wurfel MM. COPD disease severity and innate immune response to pathogen-associated molecular patterns. Int J COPD. 2016;11:467–77.CrossRef Fan VS, Gharib SA, Martin TR, Wurfel MM. COPD disease severity and innate immune response to pathogen-associated molecular patterns. Int J COPD. 2016;11:467–77.CrossRef
24.
go back to reference Tak LM, Bakker SJ, Slaets JP, Rosmalen JG. Is high-sensitive C-reactive protein a biomarker for functional somatic symptoms? A population-based study. Brain Behav Immun. 2009;23(7):1014–9.CrossRefPubMed Tak LM, Bakker SJ, Slaets JP, Rosmalen JG. Is high-sensitive C-reactive protein a biomarker for functional somatic symptoms? A population-based study. Brain Behav Immun. 2009;23(7):1014–9.CrossRefPubMed
25.
go back to reference Agusti A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7(5):e37483.CrossRefPubMedPubMedCentral Agusti A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7(5):e37483.CrossRefPubMedPubMedCentral
26.
go back to reference Duivis HE, de Jonge P, Penninx BW, Na BY, Cohen BE, Whooley MA. Depressive symptoms, health behaviors, and subsequent inflammation in patients with coronary heart disease: prospective findings from the heart and soul study. Am J Psychiatry. 2012;168(9):913–20.CrossRef Duivis HE, de Jonge P, Penninx BW, Na BY, Cohen BE, Whooley MA. Depressive symptoms, health behaviors, and subsequent inflammation in patients with coronary heart disease: prospective findings from the heart and soul study. Am J Psychiatry. 2012;168(9):913–20.CrossRef
27.
go back to reference Illi J, Miaskowski C, Cooper B, et al. Association between pro- and anti-inflammatory cytokine genes and a symptom cluster of pain, fatigue, sleep disturbance, and depression. Cytokine. 2012;58(3):437–47.CrossRefPubMedPubMedCentral Illi J, Miaskowski C, Cooper B, et al. Association between pro- and anti-inflammatory cytokine genes and a symptom cluster of pain, fatigue, sleep disturbance, and depression. Cytokine. 2012;58(3):437–47.CrossRefPubMedPubMedCentral
28.
go back to reference Bremmer MA, Beekman AT, Deeg DJ, et al. Inflammatory markers in late-life depression: results from a population-based study. J Affect Disord. 2008;106(3):249–55.CrossRefPubMed Bremmer MA, Beekman AT, Deeg DJ, et al. Inflammatory markers in late-life depression: results from a population-based study. J Affect Disord. 2008;106(3):249–55.CrossRefPubMed
29.
go back to reference John U, Meyer C, Rumpf HJ, Hapke U. Smoking, nicotine dependence and psychiatric comorbidity--a population-based study including smoking cessation after three years. Drug Alcohol Depend. 2004;76(3):287–95.CrossRefPubMed John U, Meyer C, Rumpf HJ, Hapke U. Smoking, nicotine dependence and psychiatric comorbidity--a population-based study including smoking cessation after three years. Drug Alcohol Depend. 2004;76(3):287–95.CrossRefPubMed
30.
go back to reference DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160(14):2101–7.CrossRefPubMed DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160(14):2101–7.CrossRefPubMed
31.
go back to reference Naberan K, Azpeitia A, Cantoni J, Miravitlles M. Impairment of quality of life in women with chronic obstructive pulmonary disease. Respir Med. 2012;106(3):367–73.CrossRefPubMed Naberan K, Azpeitia A, Cantoni J, Miravitlles M. Impairment of quality of life in women with chronic obstructive pulmonary disease. Respir Med. 2012;106(3):367–73.CrossRefPubMed
32.
go back to reference Laurin C, Lavoie KL, Bacon SL, et al. Sex differences in the prevalence of psychiatric disorders and psychological distress in patients with COPD. Chest. 2007;132(1):148–55.CrossRefPubMed Laurin C, Lavoie KL, Bacon SL, et al. Sex differences in the prevalence of psychiatric disorders and psychological distress in patients with COPD. Chest. 2007;132(1):148–55.CrossRefPubMed
33.
go back to reference Blinderman CD, Homel P, Billings JA, Tennstedt S, Portenoy RK. Symptom distress and quality of life in patients with advanced chronic obstructive pulmonary disease. J Pain Symptom Manage. 2009;38(1):115–23.CrossRefPubMed Blinderman CD, Homel P, Billings JA, Tennstedt S, Portenoy RK. Symptom distress and quality of life in patients with advanced chronic obstructive pulmonary disease. J Pain Symptom Manage. 2009;38(1):115–23.CrossRefPubMed
34.
go back to reference Tinetti ME, McAvay GJ, Chang SS, et al. Contribution of multiple chronic conditions to universal health outcomes. J Am Geriatr Soc. 2012;59(9):1686–91.CrossRef Tinetti ME, McAvay GJ, Chang SS, et al. Contribution of multiple chronic conditions to universal health outcomes. J Am Geriatr Soc. 2012;59(9):1686–91.CrossRef
Metadata
Title
Symptom profiles and inflammatory markers in moderate to severe COPD
Authors
Huong Q. Nguyen
Jerald R. Herting
Kenneth C. Pike
Sina A. Gharib
Gustavo Matute-Bello
Soo Borson
Ruth Kohen
Sandra G. Adams
Vincent S. Fan
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2016
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-016-0330-1

Other articles of this Issue 1/2016

BMC Pulmonary Medicine 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.